The development of classically and alternatively activated macrophages has different effects on the varied stages of radiation-induced pulmonary injury in mice

Journal of Radiation Research

Volumn 52, Issue 6, 2011, Pages 717-726

  Zhang, Hui ^a   Han, Guang ^a,b   Liu, Hui ^a   Chen, Ji ^a   Ji, Xuemei ^a   Zhou, Fuxiang ^a   Zhou, Yunfeng ^a   Xie, Conghua ^a  

^a WUHAN UNIVERSITY   (China)

^b HUBEI CANCER HOSPITAL   (China)

Author keywords

Alternative activation; Classical activation; Macrophage; Radiation induced pulmonary injury

Indexed keywords

IRRADIATION; MACROPHAGES; MAMMALS; NITRIC OXIDE; PROTEINS; RADIATION EFFECTS;

ACTIVATED MACROPHAGES; ALTERNATIVE ACTIVATION; C57BL/6 MICE; CLASSICAL ACTIVATION; DIFFERENT EFFECTS; INDUCIBLE NITRIC OXIDE SYNTHASE; MRNA LEVELS; PROTEIN LEVEL; RADIATION-INDUCED; RADIATION-INDUCED PULMONARY INJURY;

CHEMICAL ACTIVATION;

EID: 82055180507     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.11054     Document Type: Article

References (33)

1. Xie CH, et al (2006) Chinese medicine Angelica sinensis suppresses radiation-induced expression of TNF-alpha and TGF-beta1 in mice. Oncol Rep 15: 1429-1436.
2. Han G, et al (2006) Angelica sinensis down-regulates hydroxyproline and Tgfb1 and provides protection in mice with radiation-induced pulmonary fibrosis. Radiat Res 165: 546-552.
3. Rubin P, et al (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33: 99-109.
4. Chiang CS, et al (2005) Compartmental responses after thoracic irradiation of mice: strain differences. Int J Radiat Oncol Biol Phys 62: 862-871.
5. Nozaki Y, et al (1997) Nitric oxide as an inflammatory mediator of radiation pneumonitis in rats. Am J Physiol 272: L651-L658.
6. Gordon S, et al (1992) Macrophages in tissues and in vitro. Curr Opin Immunol 4: 25-32.
7. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
8. Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73: 209-212.
9. Mantovani A, et al (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
10. Bosca L, et al (2005) Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate. Toxicology 208: 249-258.
11. Mosser DM and Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
12. Wu G and Morris SM, Jr. (1998) Arginine metabolism: nitric oxide and beyond. Biochem J 336 (Pt 1): 1-17.
13. Munder M, Eichmann K and Modolell M (1998) Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 160: 5347-5354.
14. Goerdt S, et al (1999) Alternative versus classical activation of macrophages. Pathobiology 67: 222-226.
15. Raes G, et al (2002) FIZZ1 and Ym as tools to discriminate between differentially activated macrophages. Dev Immunol 9: 151-159.
16. Edwards JP, et al (2006) Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 80: 1298-1307.
17. Rube CE, et al (2004) Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. Strahlenther Onkol 180: 442-448.
18. Lorimore SA, et al (2001) Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects? Oncogene 20: 7085-7095.
19. Bronte V and Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654.
20. Hesse M, et al (2001) Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 167: 6533-6544.
21. Hesse M, et al (2000) NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am J Pathol 157: 945-955.
22. Stein M, et al (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287-292.
23. Gordon S and Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
24. Noel W, et al (2004) Alternatively activated macrophages during parasite infections. Trends Parasitol 20: 126-133.
25. Sime PJ and O'Reilly KM (2001) Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 99: 308-319.
26. Miller MJ, et al (1993) Nitric oxide: the Jekyll and Hyde of gut inflammation. Agents Actions 39 Spec No: C180-C182.
27. Vallance P (2003) Nitric oxide: therapeutic opportunities. Fundam Clin Pharmacol 17: 1-10.
28. Salvemini D, et al (1996) Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 118: 829-838.
29. Gil'iano N, et al (2005) [Modification of cellular radiosensitivity by NO-synthase inhibitors]. Radiats Biol Radioecol 45: 63-67.
30. Giliano NY, Konevega LV and Noskin LA (2010) Dynamics of intracellular superoxide and NO content in human endotheliocytes and carcinoma cells after treatment with NO synthase inhibitors. Bull Exp Biol Med 149: 78-81.
31. Boucher JL, et al (1994) N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem Biophys Res Commun 203: 1614-1621.
32. Huynh NN, et al (2009) The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br J Pharmacol 156: 84-93.
33. Kitowska K, et al (2008) Functional role and species-specific contribution of arginases in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L34-L45.